Pharmacologic management of chronic insomnia

Southern Medical Journal

Volumn 99, Issue 12, 2006, Pages 1373-1377

  Taylor, James R ^a   Vazquez, Cristina M ^b   Campbell, Kendall M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE

Author keywords

Hypnotics; Insomnia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; FLUVOXAMINE; PLACEBO; QUAZEPAM; RAMELTEON; TEMAZEPAM; TRAZODONE; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

AMNESIA; BEHAVIOR THERAPY; BLURRED VISION; CLINICAL TRIAL; COGNITION; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG TOLERANCE; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; NAUSEA; ORTHOSTATIC HYPOTENSION; REBOUND; REVIEW; SIDE EFFECT; XEROSTOMIA;

HUMANS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33845949420     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000243131.25116.bd     Document Type: Review

References (43)

1. Costa e Silva JA, Chase M, Sartorius M, et al. Special report from a symposium held by the World Health Organization and World Federation of Sleep Research Societies: an overview of insomnias and related disorders: recognition, epidemiology, and rational management. Sleep 1996;19:412-416.
2. Morin CM, Culbert JP, Schwartz SM. Nonpharmacolgical interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994;151:1172-1180.
3. Roth T. New developments for treating sleep disorders. J Clin Psychiatry 2001;62(Suppl 10):3-4.
4. Shochat T, Umphress J, Israel AG, et al. Insomnia in primary care patients. Sleep 1999;22(Suppl 2):S359-S365.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC, American Psychiatric Association, 1994.
6. The International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manual. Rochester, Minn, American Sleep Disorders Association, 1997.
7. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 1991;52(Suppl):38-41.
8. Meddelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992;53(Suppl):8-9.
9. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-2177.
10. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-233.
11. Prescribing information. Ambien (zolpidem). New York, NY, Sanofi Synthelabo, March 2004.
12. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-199.
13. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000;23:1087-1096.
14. Perlis ML, McCall WV, Krystal AD, et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004;65:1128-1137.
15. Prescribing information. Sonata (zaleplon). Philadelphia, Pa, Wyeth Pharmaceuticals, March 2006.
16. Elie R, Ruther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic: Zaleplon Clinical Study Group. J Clin Psychiatry 1999;60:536-544.
17. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia. Sleep Med 2000;1:41-49.
18. Walsh JK, Pollak CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23:17-21.
19. Prescribing information. Lunesta (eszopiclone). Marlborough, Mass, Sepracor, February 2005.
20. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study of adults with chronic insomnia. Sleep 2003;26:793-799.
21. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-1991.
22. Scharf M, McCall WV, Erman M, et al. Patient-reported efficacy of eszopiclone (ESZ) in elderly patients with chronic insomnia (abstract). J Am Geriatr Soc 2004;52:S14.
23. Erman M, Rosenburg R, Caron J. Polysomnographic and patient-reported evaluation of the efficacy and safety of eszopiclone in elderly subjects with chronic insomnia (abstract). Sleep 2004;27(Suppl):A257.
24. Roth T, Krystal A, Walsh J, et al. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety (abstract). Sleep 2004;27(Suppl):A260.
25. Prescribing information. Rozerem (ramelteon). Lincolshire, Ill, Takeda, August 2005.
26. Roth T, Seiden D, Weigand S, et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia (abstract). 45th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); June 6-9, 2005, Boca Raton, Fla.
27. Zammit G, Roth T, Erman M, et al. Polysomnogaraphy and outpatient study to determine the efficacy of ramelteon in adults with chronic insomnia (abstract). 158th Annual Meeting of the American Psychiatric Association: New Research Abstracts; May 21-26, 2005, Atlanta, p227.
28. Roth T, Seiden D, Zee P, et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients (abstract). J Am Geriatr Soc 2005;53(Suppl 4):S25.
29. Zammit G, Roth T, Erman M, et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia (abstract). Sleep 2005;28:A228-A229.
30. Seiden D, Zee P, Weigand S, et al. Double-blind, placebo-controlled outpatient clinical trial of ramelteon for the treatment of chronic insomnia in an elderly population (abstract). Sleep 2005;28:A228.
31. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24.
32. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-1072.
33. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998;13:191-198.
34. Montgomery I, Oswald I, Morgan K, et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983;16:139-144.
35. Rickels K, Morris RJ, Newman H, et al. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol 1983;23:234-242.
36. Kudo Y, Kurihara M. Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study. J Clin Pharmacol 1990;30:1041-1048.
37. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511-515.
38. Roth T, Roehrs T, Koshorek G, et al. Sedative effects of antihistamines. J Allergy Clin Immunol 1987;80:94-98.
39. Mishima K, Satoh K, Shimizu T, et al. Hypnotic and hypothermic action of daytime-administered melatonin. Psychopharmacology (Berl) 1997;133:168-171.
40. Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603.
41. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998;21:52-68.
42. Andrade C, Srihari BS, Reddy KP, et al. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 2001;62:41-45.
43. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32:680-691.